Innovating Works

EpiGlioT

Financiado
Epigenetic Glioblastoma Therapeutics
The goal of this project is to develop a successful treatment that combats the progression of glioblastoma and improve patients’ quality of life. Glioblastoma, the most malignant brain tumour, leads to disproportionately high morb... The goal of this project is to develop a successful treatment that combats the progression of glioblastoma and improve patients’ quality of life. Glioblastoma, the most malignant brain tumour, leads to disproportionately high morbidity in patients and impacts the economy through high mortality rates. The available treatment options are highly ineffective and pose a significant challenge to the healthcare budgets of all nations. Beactica aims to address this challenge by developing novel compound to inhibit the overexpressed in cancers protein LSD1. Beactica’s programme is based on a verified LSD1 knockdown technique and proves markedly more effective with glioblastoma clones that are resistant to other therapeutics. This way, Beactica’s compounds effectively clear cancer cells from which brain tumour might grow anew and will reduce the risk of relapses. This therapy will improve intervention outcomes for patients and lower additional treatment and healthcare costs including longer hospitalisation and further medical procedures. This programme is unique and there are no competitors using the same approach to treat glioblastoma by knockdown of the LSD1 protein with a small molecule. The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for out-licensing. Beactica plans to apply for SME Phase 2 grant to take the lead compound through the clinical Phase I/IIa, and then reach the pharmaceutical market by an agreement with a strong licence partner. Beactica has an established business development contact network and has already gained trust of external investors in this innovative technology. The problem of cancer is growing dramatically and has been highlighted in the recent policy focus by the European Commission and the World Health Organisation. In this light, Beactica is assured of the significant impact the LSD1 knockdown innovation will have on the glioblastoma burden in Europe and worldwide. ver más
30/09/2018
Beactica
71K€
Duración del proyecto: 3 meses Fecha Inicio: 2018-06-01
Fecha Fin: 2018-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2018-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 71K€
Líder del proyecto
BEACTICA THERAPEUTICS AB No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5